TW200626605A - Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors - Google Patents

Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors

Info

Publication number
TW200626605A
TW200626605A TW094134114A TW94134114A TW200626605A TW 200626605 A TW200626605 A TW 200626605A TW 094134114 A TW094134114 A TW 094134114A TW 94134114 A TW94134114 A TW 94134114A TW 200626605 A TW200626605 A TW 200626605A
Authority
TW
Taiwan
Prior art keywords
preparation
kinase inhibitors
pharmaceutical use
optionally substituted
azaindole derivatives
Prior art date
Application number
TW094134114A
Other languages
English (en)
Inventor
Conception Nemecek
William A Metz
Sylvie Wentzler
Dominique Lesuisse
Youssef El-Ahmad
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TW200626605A publication Critical patent/TW200626605A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW094134114A 2004-10-01 2005-09-30 Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors TW200626605A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410386A FR2876103B1 (fr) 2004-10-01 2004-10-01 Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
TW200626605A true TW200626605A (en) 2006-08-01

Family

ID=34952807

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094134114A TW200626605A (en) 2004-10-01 2005-09-30 Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors

Country Status (20)

Country Link
US (2) US7786114B2 (zh)
EP (1) EP1799691B1 (zh)
JP (1) JP2008514683A (zh)
KR (1) KR20070067116A (zh)
CN (1) CN101052642A (zh)
AR (1) AR050963A1 (zh)
AT (1) ATE538125T1 (zh)
AU (1) AU2005291137A1 (zh)
BR (1) BRPI0516841A (zh)
CA (1) CA2580831A1 (zh)
EA (1) EA200700758A1 (zh)
FR (1) FR2876103B1 (zh)
IL (1) IL182054A0 (zh)
MA (1) MA28941B1 (zh)
MX (1) MX2007003872A (zh)
NO (1) NO20072053L (zh)
SG (1) SG155946A1 (zh)
TW (1) TW200626605A (zh)
WO (1) WO2006037875A1 (zh)
ZA (1) ZA200702596B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2483407A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
AU2011263546B2 (en) * 2010-06-10 2015-01-22 Midatech Limited Peptide-carrying nanoparticles
EP2601192B1 (en) 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP2675275B1 (en) 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
KR101964479B1 (ko) 2011-03-31 2019-04-01 카나 바이오사이언스, 인코포레이션 신규 푸라논 유도체
US9365581B2 (en) 2013-05-02 2016-06-14 The Regents Of The University Of Michigan Deuterated amlexanox
EP3851437A3 (en) * 2013-11-13 2021-11-03 Vertex Pharmaceuticals Incorporated Methods of preparing 1h-pyrrolo[2,3-b]pyridine derivates
EP3100742B1 (en) 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
ES2763527T3 (es) 2014-04-04 2020-05-29 Univ Michigan Regents Inhibidores de molécula pequeña de mcl-1 y usos de los mismos
EP3453710B1 (en) 2014-09-17 2022-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN107001330A (zh) * 2014-09-17 2017-08-01 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3407974A4 (en) 2016-01-29 2019-08-28 The Regents Of The University Of Michigan ANALOGUES OF AMLEXANOX

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263759B1 (en) 1999-12-24 2010-09-08 Aventis Pharma Limited Azaindoles
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003024969A1 (en) * 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US7361671B2 (en) * 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids

Also Published As

Publication number Publication date
SG155946A1 (en) 2009-10-29
US20100256141A1 (en) 2010-10-07
MA28941B1 (fr) 2007-10-01
ZA200702596B (en) 2009-09-30
JP2008514683A (ja) 2008-05-08
WO2006037875A1 (fr) 2006-04-13
BRPI0516841A (pt) 2008-09-23
US7786114B2 (en) 2010-08-31
AU2005291137A1 (en) 2006-04-13
IL182054A0 (en) 2007-07-24
US20080045561A1 (en) 2008-02-21
FR2876103B1 (fr) 2008-02-22
CA2580831A1 (fr) 2006-04-13
CN101052642A (zh) 2007-10-10
NO20072053L (no) 2007-04-20
MX2007003872A (es) 2007-06-07
KR20070067116A (ko) 2007-06-27
EA200700758A1 (ru) 2007-10-26
EP1799691B1 (fr) 2011-12-21
EP1799691A1 (fr) 2007-06-27
FR2876103A1 (fr) 2006-04-07
ATE538125T1 (de) 2012-01-15
AR050963A1 (es) 2006-12-06

Similar Documents

Publication Publication Date Title
TW200626605A (en) Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
TN2010000044A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
TW200744604A (en) P38 MAP kinase inhibitors and methods for using the same
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
TW200738684A (en) Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
SG140591A1 (en) Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
TW200612936A (en) Indole derivatives
TW200738685A (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MX2012004089A (es) Inhibidores de hsp90.
JO2822B1 (en) Inhibitors of the enzyme kinase P70 S6 and AKT
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
SG196785A1 (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4, 3-c] isoquinoline derivatives
TW200602344A (en) Novel pyrrolo(2, 3-b)pyridine derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
UA101162C2 (ru) Производные индол-2-она, двузамещенные в положении 3, их получение и применение в терапии
TW200628153A (en) Novel compounds
MX2009003283A (es) Nuevos derivados imidazolonas, su preparacion como medicamentos, composiciones farmaceuticas y uso como inhibidores de proteinas quinasas, principalmente cdc7.
TW200734336A (en) 6-Heteroarylpyridoindolone derivatives, preparation thereof and therapeutic use thereof
GB0308201D0 (en) Novel compounds
MY150988A (en) Novel derivatives of ( bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors
MX2009004625A (es) Derivados de 3-amino-pirazol-4-carboxamida utiles como inhibidores de proteina cinasas.